A Study to Evaluate the Efficacy and Safety of Rosuvastatin in the Long-Term Treatment of Hypercholesterolaemic Subjects With Coronary Heart Disease as Measured by Intravascular Ultrasonography

INTERVENTION: Intervention name : Rosuvastatin Dosage And administration of the intervention : Oral CONDITION: Hypercholesteremia PRIMARY OUTCOME: Safety/Efficacy Primary Outcomes: Percentage change from baseline (before the start of rosuvastatin treatment) to Week 76 in the plaque volume (PV) Secondary Outcomes: Change from baseline to Week 76 in PV in the target lesion; Percentage changes from baseline to specified measurement time points in TC, LDL‐C, VLDL‐C, HDL‐C, non HDL‐C, TG and RLP‐C; Changes in hs‐CRP from baseline to specified measurement time points; Safety; Adverse events, subjective symptoms/objective findings, physical tests), blood tests (hematology, clinical chemistry, glucose metabolism test), urinalysis INCLUSION CRITERIA: Ages Eligible for Study: 20 Years ‐ 75 Years Genders Eligible for Study: Both Criteria INCLUSION CRITERIA: ‐ Signed written informed consent, ‐ 20 to 75 years old, ‐ Plan to undergo coronary angiography (CAG) or PCI and LDL‐C = 140 mg/dL (untreated patients) or LDL‐C =100 mg/dL (treated patients Exclusion Criteria: ‐ Acute myocardial infarction within 72 hours after the onset, ‐ Heart failure of NYHA Class III or above, ‐ Serious arrhythmia, ‐ Being treated with LDL‐apheresis ‐ History of serious reaction or hypersensitivity to other HMG‐CoA reductase inhibitors.